In the #European #Union one can notice a change in perspective regarding #CBD, its danger and use. This can be traced back to a long-awaited #judgment by the Court of Justice of the European Union (ECJ) in #2020.
In #November 2020 the #ECJ concluded that CBD extracted from the #Cannabis #sativa #plant in its entirety — and not solely from its #fiber and #seeds — cannot be regarded as a narcotic drug. Until recently, the #UN placed cannabis and cannabis resin in the highest danger class of narcotic drugs established by the 1961 UN Single Convention on Narcotic Drugs. Following the ECJ ruling and a recommendation of the World #Health Organization (#WHO), the UN Commission on Narcotic Drugs downgraded cannabis and cannabis resin from the highest to the lowest danger class in December 2020.
Now, The European Commission (EC) has reacted to the ECJ ruling and signaled that it will no longer classify CBD as a narcotic drug in the #future. It stated: “in light of the recent Court’s judgment in case C-663/184, the Commission has reviewed its preliminary assessment and concludes that #cannabidiol should not be considered as drug within the meaning of the United Nations Single Convention on Narcotic Drugs of 1961 in so far as it does not have #psychotropic effect.”
These developments are expected to open the European #market to CBD. However, prior to selling a CBD-infused food product in the European Union, each product requires pre-market authorization under the EU novel food regulation. To date, CBD has not been approved as a novel #food. However, in the light of the EC’s re-evaluation, it can be expected that CBD will be added to the list of approved products. Generally, it takes 3 to 4 years for an ingredient to gain novel food status and it is uncertain when a final decision will be issued in the pending cases.
Distributed by: Cannabis Broadcast Station/ Infinity Broadcast Network